CD274 and cancer: A recently published meta‐analysis, led by a Chinese group, compared the OS differences between anti‐PD1 and anti‐PD‐L1 across different cancer types in 19 randomized clinical trials involving 11 379 patients, regardless of the number of previous treatments.24